BioSpace News Archive

SimBioSys ® , the precision medicine company behind TumorScope®, the 4D tumor modeling platform for treatment planning, announced today it has been awarded a $2M Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI), part of the National Institutes of Health.

Ionpath, a pioneer in high-definition spatial proteomics, today announced that the results of several studies enabled by multiplexed ion beam imaging (MIBI™) technology will be presented in posters at this week’s annual meeting of the Society for Immunotherapy of Cancer (SITC).

A Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the company is scheduled to participate in the following investor conferences in November.

Avenue Therapeutics, Inc. today announced the closing of the acquisition of Baergic Bio, Inc. (“Baergic Bio”) pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech, Inc.

SAB Biotherapeutics today announced the company will be attending and presenting at this year’s U.S. Pharma Partnering Summit, being held on Nov. 17-18 in Boston, MA.

Processa Pharmaceuticals, Inc. announces positive gastric emptying results from its PCS12852 Phase 2A trial in patients with moderate to severe gastroparesis.

Immunomic Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the ITI-3000 program for the treatment of patients with Merkel cell carcinoma.

Neovasc Inc. announced that the Centers for Medicare and Medicaid Services has assigned the Neovasc Reducer™ implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.

NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in Philadelphia, Pennsylvania.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational drug LX9211, a novel, highly selective inhibitor of adaptor-associated kinase 1 (AAK1), will be presented during a podium presentation at the 16th Annual Pain Therapeutics Summit in Washington, D.C.